Cargando…
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice
Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...
Autores principales: | Kolomansky, Albert, Kaye, Irit, Ben-Califa, Nathalie, Gorodov, Anton, Awida, Zamzam, Sadovnic, Ofer, Ibrahim, Maria, Liron, Tamar, Hiram-Bab, Sahar, Oster, Howard S., Sarid, Nadav, Perry, Chava, Gabet, Yankel, Mittelman, Moshe, Neumann, Drorit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604358/ https://www.ncbi.nlm.nih.gov/pubmed/33193330 http://dx.doi.org/10.3389/fimmu.2020.561294 |
Ejemplares similares
-
Erythropoietin receptor in B cells plays a role in bone remodeling in mice
por: Deshet-Unger, Naamit, et al.
Publicado: (2020) -
Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible
por: Kolomansky, Albert, et al.
Publicado: (2020) -
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice
por: Awida, Zamzam, et al.
Publicado: (2021) -
Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice
por: Awida, Zamzam, et al.
Publicado: (2022) -
Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss
por: Deshet-Unger, Naamit, et al.
Publicado: (2016)